Yamashita Shinichi, Ioritani Naomasa, Oikawa Katsuhiko, Aizawa Masataka, Endoh Mareyuki, Arai Yoichi
Department of Urology, Sendai Shakaihoken Hospital, Sendai, Japan.
Int J Urol. 2007 Aug;14(8):679-83. doi: 10.1111/j.1442-2042.2007.01805.x.
The aim of the study was to evaluate the clinicopathological and prognostic significance of morphological subtyping of papillary renal cell carcinoma (PRCC).
The patients treated for renal cell carcinoma in our department from January 1985 to March 2006 were evaluated retrospectively. Thirty-two of the 591 patients (5.4%) were diagnosed with PRCC. To determine the prognostic factors, we re-evaluated the pathological stage according to the 2002 TNM classification of malignant tumors, and the tumor type of renal cell carcinoma according to the 2004 World Health Organization histological classification. Survival was analysed using the Kaplan-Meier method and the log-rank test.
The age at diagnosis ranged from 33 to 81 years (median: 63 years old) and the follow-up time after the surgical treatment ranged from 4 to 191 months (median: 54 months). The cancer-specific 5-year survival rate of the 32 PRCC patients was 74%. Pathologically, 17 patients (53%) and 15 patients (47%) were diagnosed with type 1 and type 2 PRCC, respectively. The type 2 PRCC patients had a significantly higher tumor grade (P < 0.001), a more advanced stage (P < 0.001), more frequent vascular invasion (P < 0.001), and a higher sarcomatoid component (P = 0.038) compared to the type 1 PRCC patients. The type 1 patients had a better cancer-specific 5-year survival rate than the type 2 patients (94% vs 50%) (P = 0.008).
The morphological subtyping of PRCC is significantly associated with clinicopathological features and the prognosis. Our results provide evidence of the clinical utility of dividing PRCC into two subtypes.
本研究旨在评估乳头状肾细胞癌(PRCC)形态学亚型的临床病理特征及预后意义。
回顾性分析1985年1月至2006年3月在我科接受治疗的肾细胞癌患者。591例患者中有32例(5.4%)被诊断为PRCC。为确定预后因素,我们根据2002年恶性肿瘤TNM分类重新评估病理分期,并根据2004年世界卫生组织组织学分类重新评估肾细胞癌的肿瘤类型。采用Kaplan-Meier法和对数秩检验分析生存率。
诊断时年龄为33至81岁(中位数:63岁),手术治疗后的随访时间为4至191个月(中位数:54个月)。32例PRCC患者的癌症特异性5年生存率为74%。病理上,分别有17例(53%)和15例(47%)患者被诊断为1型和2型PRCC。与1型PRCC患者相比,2型PRCC患者的肿瘤分级显著更高(P<0.001)、分期更晚(P<0.001)、血管侵犯更频繁(P<0.001)且肉瘤样成分更高(P=0.038)。1型患者的癌症特异性5年生存率优于2型患者(94%对50%)(P=0.008)。
PRCC的形态学亚型与临床病理特征及预后显著相关。我们的结果为将PRCC分为两个亚型的临床实用性提供了证据。